Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial

Pharmacological treatments for depression have insufficient efficacy in 30–40% of patients and fail to reverse cognitive deficits. Erythropoietin (EPO) has neurotrophic actions and aids neurocognitive function. The aim of this exploratory study was to determine whether recombinant human EPO improves...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Miskowiak, Kamilla W, Vinberg, Maj, Christensen, Ellen M, Bukh, Jens D, Harmer, Catherine J, Ehrenreich, Hannelore, Kessing, Lars V
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3988543/
https://ncbi.nlm.nih.gov/pubmed/24322509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2013.335
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados